Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis

•Gut Microbiota (GM) has an important role in liver diseases progression.•Notable differences in GM and diversity exist between healthy individuals and cirrhosis patients.•Changes in GM are associated with an increased risk of mortality within 90 days.•Firmicutes/Bacteroidetes and Firmicutes/Proteob...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinics (São Paulo, Brazil) Brazil), 2024-01, Vol.79, p.100471, Article 100471
Hauptverfasser: Mantovani, Augusto, Longo, Larisse, Thoen, Rutiane Ullmann, Rampelotto, Pabulo Henrique, Salinas, Raul, Guerreiro, Gabriel Tayguara Silveira, Álvares-da-Silva, Mário Reis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Gut Microbiota (GM) has an important role in liver diseases progression.•Notable differences in GM and diversity exist between healthy individuals and cirrhosis patients.•Changes in GM are associated with an increased risk of mortality within 90 days.•Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria predict hepatic decompensation and mortality. Some evidence suggests an association between gut dysbiosis and cirrhosis progression. The authors investigated Gut Microbiome (GM) influence on 90-day mortality and hospitalization/rehospitalization rates in cirrhotic patients. Compensated/decompensated outpatients and decompensated inpatients were prospectively included and compared to healthy controls. Clinical, laboratory, GM, and two ratios between phyla were evaluated. Patients were followed up for 90 days for hospitalization/rehospitalization and mortality. 165 individuals were included (50 compensated, 49 decompensated outpatients; 36 decompensated inpatients; 30 healthy), 48.5 % female, mean age was 61, main cirrhosis etiology was hepatitis C (27.3 %), and mostly Child-Pugh (CP) B patients, median MELD of 13. As liver disease progressed, microbiota diversity decreased between the groups (p = 0.05; p < 0.004). There were 9 deaths and 22 hospitalizations or rehospitalizations. GM composition had correlation with norfloxacin (p = 0.36, p = 0.04), encephalopathy (p = 0.31, p = 0.01), lactulose (p = 0.26, p = 0.01), 90-day mortality (p = 0.22, p = 0.04), CP (p = 0.17, p = 0.01), previous 6-month antibiotic use (p = 0.16, p = 0.01), MELD (p = 0.145, p = 0.01), ALBI (p = 0.1, p = 0.04) and 90-day hospitalization/rehospitalization (p = 0.08, p = 0.03). Firmicutes/Bacteroidetes (F/B) and Firmicutes/Proteobacteria (F/P) ratios were progressively lower and more significant and had an association with 90-day mortality (p < 0.001). Three MELD set-points (≥ 15, 18 and 20) were significantly associated with both ratios, with similar accuracies. GM dysbiosis was associated with higher CP, MELD, 90-day mortality and hospitalization/rehospitalization. F/B and F/P ratios were associated with 90-day mortality.
ISSN:1807-5932
1980-5322
1980-5322
DOI:10.1016/j.clinsp.2024.100471